Ginsenoside composition, and preparation method and use thereof

US2017368083A1 · US · A1

Patent metadata
FieldValue
Publication numberUS-2017368083-A1
Application numberUS-201615388094-A
CountryUS
Kind codeA1
Filing dateDec 22, 2016
Priority dateJun 24, 2016
Publication dateDec 28, 2017
Grant date

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention relates to the pharmaceutical field, and in particular to a ginsenoside composition, and preparation method and use thereof. The ginsenoside composition comprises rare ginsenosides Rh4, Rk3, Rk1 and Rg5. By conducting a systematic research on the change in active ingredients during the steaming process of ginseng and applying response surface to design experiments so as to optimize the ginseng processing process, a processing method wherein there is the most significant change in ginsenoside ingredients relative to the original medicinal material, and especially a processing method for efficiently obtaining rare ginsenoside ingredients, is unexpectedly discovered in the present invention. Through later screening of pharmacological activities, the inventors further unexpectedly discovered that the processed ginseng product rich in rare ginsenosides has a significant efficacy in invigorating kidney yang.

First claim

Opening claim text (preview).

1 . A ginsenoside composition comprising rare ginsenosides Rh4, Rk3, Rk1 and Rg5. 2 . The ginsenoside composition according to claim 1 , further comprising ginsenosides Rf, Rb1, Rc, Rb2 and Rd. 3 . The ginsenoside composition according to claim 1 , further comprising ginsenosides Rg1 and Re. 4 . The ginsenoside composition according to claim 3 , wherein the total content of the rare ginsenosides Rh4, Rk3, Rk1 and Rg5 is greater than 42.55 mg/g; the total content of the ginsenosides Rf, Rb1, Rc, Rb2 and Rd is less than 10 mg/g; and the total content of the ginsenosides Rg1 and Re is less than 0.35 mg/g. 5 . The ginsenoside composition according to claim 1 , which is prepared by a method comprising steaming ginseng for 1 to 10 h at 90 to 130° C., wherein the steaming is carried out for 1 to 9 times. 6 . The ginsenoside composition according to claim 5 , wherein the method further comprises pulverizing the steamed ginseng and passing the pulverized ginseng through a 100-mesh screen. 7 . The ginsenoside composition according to claim 5 , wherein the method further comprises cutting the steamed ginseng into slices and extracting the slices with water or ethanol to obtain an extract. 8 . A process for increasing thymus or spleen index, plasma SOD activity and/or plasma cAMP/cGMP level in a subject in need thereof, comprising administering the subject a medicament and/or healthcare product comprising the ginsenoside composition according to claim 1 . 9 . A process for treating deficiency of kidney yang in a subject in need thereof, comprising administering the subject a medicament and/or healthcare product comprising the ginsenoside composition according to claim 1 . 10 . The process according to claim 8 , wherein the medicament is administrated at a dosage of 0.2 to 2 g/kg/d for a non-human animal subject, and at a human equivalent dosage of 0.02 to 0.2 g/kg/d for a human subject. 11 . The process according to claim 9 , wherein the medicament is administrated at a dosage of 0.2 to 2 g/kg/d for a non-human animal subject, and at a human equivalent dosage of 0.02 to 0.2 g/kg/d for a human subject.

Assignees

Inventors

Classifications

  • A61K31/704Primary

    attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)} · CPC title

  • Panax (ginseng) · CPC title

  • Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine · CPC title

  • of the kidneys · CPC title

  • Food compositions, function of food ingredients or processes for food or foodstuffs · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US2017368083A1 cover?
The present invention relates to the pharmaceutical field, and in particular to a ginsenoside composition, and preparation method and use thereof. The ginsenoside composition comprises rare ginsenosides Rh4, Rk3, Rk1 and Rg5. By conducting a systematic research on the change in active ingredients during the steaming process of ginseng and applying response surface to design experiments so as to…
Who is the assignee on this patent?
Infinitus China Co Ltd
What technology area does this patent fall under?
Primary CPC classification A61K31/704. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Thu Dec 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).